sb 203580 has been researched along with butaprost in 1 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (butaprost) | Trials (butaprost) | Recent Studies (post-2010) (butaprost) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 161 | 0 | 46 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Birnbaumer, L; Edwards, RA; Hoang, B; Trinh, A | 1 |
1 other study(ies) available for sb 203580 and butaprost
Article | Year |
---|---|
Decreased MAPK- and PGE2-dependent IL-11 production in Gialpha2-/- colonic myofibroblasts.
Topics: 16,16-Dimethylprostaglandin E2; Alprostadil; Animals; Cells, Cultured; Colon; Cyclic AMP; Dinoprostone; Dose-Response Relationship, Drug; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; Flavonoids; GTP-Binding Protein alpha Subunit, Gi2; Imidazoles; Interleukin-11; Interleukin-1beta; Intestine, Small; Methyl Ethers; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Pyridines; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP4 Subtype; RNA, Messenger; Signal Transduction; Transforming Growth Factor beta | 2007 |